Description

Halotestin 5 mg by Swiss Healthcare contains Fluoxymesterone, a highly potent oral anabolic-androgenic steroid (AAS), historically used in the treatment of male hypogonadism, delayed puberty, and certain breast cancers. In research settings, Halotestin is studied for its strong androgenic activity, aggression modulation, neural stimulation, and power output enhancement—particularly in short-term performance and strength-focused models.

Fluoxymesterone is known for its very high androgenic rating, minimal estrogenic activity, and non-aromatizing structure, making it unique among oral AAS compounds. It is 17-alpha alkylated for oral bioavailability and must be used with attention to liver markers in extended studies.

Swiss Healthcare manufactures Halotestin under pharmaceutical-grade standards, offering 40 oral tablets, each precisely dosed at 5 mg for research involving maximum androgenic effect with minimal water retention.

Product Details

• Active Ingredient: Fluoxymesterone (Halotestin)

• Concentration per Tablet: 5 mg

• Form: Oral tablets

• Package Size: 40 tablets per bottle

Pharmacokinetics

Halotestin has a half-life of approximately 9.2 hours, with rapid onset and strong androgen receptor affinity. It does not convert to estrogen, and its neurostimulatory properties are often observed in studies involving central nervous system activation and aggression response. It is highly hepatotoxic, requiring careful handling in all research protocols.

Usage Recommendations

• Typical Research Dosage (historical reference): 10–30 mg per day

• Current Use: For research and laboratory purposes only

• Administration: Oral

Disclaimer

This product is intended strictly for research and laboratory use only. It is not approved for human use or therapeutic consumption. Not suitable for individuals under 18, pregnant or breastfeeding women, or those with liver, cardiovascular, or hormonal disorders. Always follow applicable regulations and professional safety protocols.